Last reviewed 2026-05-22 · How we verify

Secukizumab

Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1 active Biologic ✓ Verified May 2026

Secukizumab is a Biologic drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University. It is currently in Phase 1 development.

Secukizumab is a medication being studied in clinical trials for the treatment of psoriasis in patients over 70 years old. A multicenter head-to-head comparison study (NCT06811558) is comparing the efficacy of Secukizumab to Ixekizumab in this patient population.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Secukizumab
Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Modality	Biologic
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Secukizumab CI brief — competitive landscape report
Secukizumab updates RSS · CI watch RSS
Second Affiliated Hospital, School of Medicine, Zhejiang University portfolio CI

Frequently asked questions about Secukizumab

What is Secukizumab?

Secukizumab is a Biologic drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University.

Who makes Secukizumab?

Secukizumab is developed by Second Affiliated Hospital, School of Medicine, Zhejiang University (see full Second Affiliated Hospital, School of Medicine, Zhejiang University pipeline at /company/second-affiliated-hospital-school-of-medicine-zhejiang-university).

What development phase is Secukizumab in?

Secukizumab is in Phase 1.

Manufacturer: Second Affiliated Hospital, School of Medicine, Zhejiang University — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing